Serum lipoproteins are not associated with the severity of asthma
ConclusionsThe current findings confirm a role of LDL as a potential biomarker in the diagnostic process for asthma, and suggest that LDL cannot be used as marker of severity of the disease. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Modeling and optimization of nebulizers' performance in non-invasive ventilation using different fill volumes: Comparative study between vibrating mesh and jet nebulizers
ConclusionsModeling of aerosol-delivery by JN and VMN using different fill-volumes in NIV circuit was successful in demonstrating the effect of different variable on dose-delivery to NIV patient. Artificial neural networks model showed that VMN increased pulmonary-bioavailability and systemic-absorption compared to JN. VMN was less affected by fill-volume change compared to JN which should be diluted to increase delivery. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

The role of sphingolipid metabolism disruption on lipopolysaccharide-induced lung injury in mice
ConclusionBlockage of sphingomyelinases and the de novo pathways improved and aggravated lung injury, respectively, putatively suggesting specific targets to therapeutic strategies in LPS-induced lung injury. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Characterisation of 40 mg/ml and 100 mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation
ConclusionAerosolized tobramycin 100 mg/ml solution delivered higher lung dose compared to tobramycin 40 mg/ml solution. Tracheal tube type or size did not influence the aerosol characteristics and delivery parameters. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults
In conclusion, BGF MDI 320/14.4/10 μg had a similar budesonide PK profile to BUD/FORM MDI 320/9 μg. No PK drug–drug interactions were observed when budesonide was added to glycopyrronium and formoterol fumarate dihydrate. These data support the use of budesonide 320 μg and 160 μg in future clinical trials of BGF MDI in COPD. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Mishandling of pMDI and DPI inhalers in asthma and COPD – Repetitive and non-repetitive errors
ConclusionsImproper inhalation technique is very common and the majority of errors made in inhalation technique are repetitive. This emphasizes the role of an ongoing verification and training of a proper inhalation technique in all patients that are regularly treated with inhalers. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Is aging a "comorbidity" of asthma?
This article will discuss the multitude of factors that justify considering aging as a comorbidity of asthma. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Use of animal models in IPF research
Publication date: Available online 5 July 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): R. Carrington, S. Jordan, S.C. Pitchford, C.P. PageAbstractIdiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis and limited treatment options. Many compounds have shown efficacy in pre-clinical models of this condition, but only Pirfenidone and Nintedanib have been approved for clinical use. It is widely accepted that the current animal models of IPF need to be improved and in this review we have critically evaluated the current state of play of preclinical models of IPF and di...
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Effect of pirfenidone on gastric emptying in a rat model
ConclusionsAdministration of pirfenidone 30 min after a meal as a single-bolus dose or a divided dose over a 90-min period blunted pirfenidone's effect on inhibition of gastric emptying in rats compared with pirfenidone administration as a single-bolus dose coincident with a meal. Decreased gastric emptying, which is associated with pirfenidone administration, may be one of the contributing factors leading to GI tolerability issues associated with pirfenidone use in humans. Modification of the dosing regimen diminished this impact and may provide insight into possible mitigation strategies to minimize GI-related toxiciti...
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

The pharmacological treatment of chronic comorbidities in COPD: mind the gap!
Conclusionsa truly comprehensive view of the complex COPD patient, hopefully capitalizing on multidimensional geriatric assessment, is needed to dissect the many components of health status impairment and to provide the optimal care. Selected screening procedures are highly desirable to identify frequently missed comorbidities. Pharmacosurveillance is an essential part of the approach to COPD and its comorbidities. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Impact of doxofylline in COPD: A pairwise meta-analysis
Publication date: August 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 51Author(s): Mario Cazzola, Luigino Calzetta, Paola Rogliani, Clive Page, Maria Gabriella MateraAbstractDoxofylline is an effective bronchodilator for relieving airway obstruction in patients with asthma or chronic obstructive pulmonary disease (COPD), and displays a better safety profile with respect to theophylline. Herein, we performed a pairwise meta-analysis of the currently available data to provide consistent and homogeneous findings on the impact of this xanthine in COPD patients. Results obtained from 820 patients were selected ...
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

In vivo and in vitro investigation of anti-inflammatory and mucus-regulatory activities of a fixed combination of thyme and primula extracts
Publication date: August 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 51Author(s): Jan Seibel, Kirill Kryshen, Judit E. Pongrácz, Martin D. LehnerAbstractHypersecretion of viscous mucus is one of the hallmark symptoms of acute and chronic bronchitis and typically develops secondary to an inflammation of the airway epithelium. Bronchipret® TP film-coated tablets (BRO), a herbal medicinal product containing a fixed combination of thyme herb and primula root extracts, has been successfully used clinically for the treatment of acute bronchitis for more than two decades. However, the underlying pharm...
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent
DiscussionBoth doses of BGF MDI were well tolerated in healthy subjects of Japanese descent and the systemic exposure to budesonide was dose proportional for BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg. The safety and pharmacokinetics for BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg in Japanese subjects were comparable to data from previous studies in Western populations, which suggests that the safety and efficacy profile of BGF MDI should be similar in Western and Japanese subjects. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Preparation, validation and user-testing of pictogram-based patient information leaflets for tuberculosis
ConclusionThe present study shows that there is significant improvement in the knowledge levels of the patients and volunteers after reading the validated leaflets. The P-PILs are found to be an effective educational tool for TB patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Oropharyngeal administration of silica in Swiss mice: A robust and reproducible model of occupational pulmonary fibrosis
Publication date: August 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 51Author(s): Sachin Karkale, Amit Khurana, Mohd Aslam Saifi, Chandraiah Godugu, Venu TallaAbstractPulmonary fibrosis (PF) is a lethal end stage of interstitial lung disease with increasing prevalence. The disease burden of PF has seen a sharp surge in the past two decades owing to entry of heavy amount of particulate matter due to industrialization and urbanization. In this work, we developed an oropharyngeal aspiration model of silica (1.5 mg/mice) induced pulmonary fibrosis as a homogeneous, reproducible, simple and alternative strateg...
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD
ConclusionsThis is the first study to demonstrate that inhaled medication can be measured in hair samples from subjects with asthma and/or COPD. The results show that hair drug concentration data could potentially provide a record of historical adherence to inhaled therapeutics. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 11, 2018 Category: Respiratory Medicine Source Type: research

The pharmacological treatment of chronic comorbidities in COPD: mind the gap!
Conclusionsa truly comprehensive view of the complex COPD patient, hopefully capitalizing on multidimensional geriatric assessment, is needed to dissect the many components of health status impairment and to provide the optimal care. Selected screening procedures are highly desirable to identify frequently missed comorbidities. Pharmacosurveillance is an essential part of the approach to COPD and its comorbidities. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 10, 2018 Category: Respiratory Medicine Source Type: research

Use of animal models in IPF research
Publication date: Available online 5 July 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): R. Carrington, S. Jordan, S.C. Pitchford, C.P. PageAbstractIdiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis and limited treatment options. Many compounds have shown efficacy in pre-clinical models of this condition, but only Pirfenidone and Nintedanib have been approved for clinical use. It is widely accepted that the current animal models of IPF need to be improved and in this review we have critically evaluated the current state of play of preclinical models of IPF and di...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Modeling and optimization of nebulizers' performance in non-invasive ventilation using different fill volumes: Comparative study between vibrating mesh and jet nebulizers
ConclusionsModeling of aerosol-delivery by JN and VMN using different fill-volumes in NIV circuit was successful in demonstrating the effect of different variable on dose-delivery to NIV patient. Artificial neural networks model showed that VMN increased pulmonary-bioavailability and systemic-absorption compared to JN. VMN was less affected by fill-volume change compared to JN which should be diluted to increase delivery. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Overreliance link between asthmatic subjects and short-acting β2 agonists
Publication date: June 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 50Author(s): Luis J. NanniniAbstractIn this brief communication, it was described the overreliance link generated between a young asthmatic subject and Short Acting Beta agonist (SABA) bronchodilator. It was an attempt to delineate the stages of this conflicting link where predominated the overreliance on SABA that might be one of the main circumstances surrounding near fatal asthma attack. New approach is needed from international guidelines to avoid development of such a problematic link between asthmatic subjects and SABA. (Source: Pulm...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension
ConclusionsActivation and inhibition of RhoA-ROCK pathway by LPA and FSD modulated the homeostasis of Th17/Treg cells via regulating STAT3/STAT5 phosphorylation in hypoxic PAH. Thus, Apart from influence of pulmonary vascular remodeling, regulation of Th17/Treg homeostasis by RhoA-ROCK pathway play a key role in hypoxic PAH. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: June 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 50Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Pulmonary hypertension in patients with interstitial lung disease
Publication date: June 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 50Author(s): Theodoros Karampitsakos, Argyrios Tzouvelekis, Serafeim Chrysikos, Demosthenes Bouros, Iraklis Tsangaris, Wassim H. FaresAbstractInterstitial lung diseases (ILDs) comprise a broad and heterogeneous group of more than two hundred diseases with common functional characteristics. Their diagnosis and management require a multidisciplinary approach. This multidisciplinary approach involves the assessment of comorbid conditions including pulmonary hypertension (PH) that exerts a dramatic impact on survival. The current World Health ...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug–device combination
Publication date: June 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 50Author(s): Pamela J. McShane, Jeffry G. Weers, Thomas E. Tarara, Alfred Haynes, Preeti Durbha, Danforth P. Miller, Tobias Mundry, Elisabeth Operschall, J. Stuart ElbornAbstractBronchiectasis is a chronic respiratory disease with heterogeneous etiology, characterized by a cycle of bacterial infection and inflammation, resulting in increasing airway damage. Exacerbations are an important cause of morbidity and are strongly associated with disease progression. Many patients with bronchiectasis suffer from two or more exacerbations per year....
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis
ConclusionOverall, we recommend EAP as the optimal choice for patients with PAH in clinical practice and PAE as suboptimal in view of their desirable performance in efficacy. Most of the combination therapies performed better than monotherapies. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Assessment of statin-induced interstitial pneumonia in patients treated for hyperlipidemia using a health insurance claims database in Japan
This study aimed to determine the frequency and risk factors for statin-induced interstitial pneumonia (IP).MethodWe conducted a retrospective cohort study using a large Japanese health insurance claims database. We determined the statin-induced IP incidence in patients treated with statins for hyperlipidemia (n = 194,814) with 12-month screening and 3-month observation periods. Statin-induced IP was defined as: (1) diagnosis with IP (ICD-10 codes: J70.2-J70.4, J84.1, and J84.9) within 3 months after starting statins; (2) steroid administration starts after starting statins; (3) undergoing laboratory tests for sialylat...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Astilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway
ConclusionsAstilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway and has potential therapeutic value for lung fibrosis treatment. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis
This study demonstrates that targeting the pathway activated by IL-5 may have a beneficial impact in eosinophilic COPD patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Effects of fluticasone propionate and budesonide on the expression of immune defense genes in bronchial epithelial cells
ConclusionsTreatment of human bronchial epithelial cells with BUD results in significantly higher expression of specific immune defense genes than treatment with FP. The differential regulation of these immune defense genes may help to explain the clinical observation that BUD and FP treatment differ with respect to the risk of developing pneumonia in COPD. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Serum lipoproteins are not associated with the severity of asthma
ConclusionsThe current findings confirm a role of LDL as a potential biomarker in the diagnostic process for asthma, and suggest that LDL cannot be used as marker of severity of the disease. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

The role of sphingolipid metabolism disruption on lipopolysaccharide-induced lung injury in mice
ConclusionBlockage of sphingomyelinases and the de novo pathways improved and aggravated lung injury, respectively, putatively suggesting specific targets to therapeutic strategies in LPS-induced lung injury. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre
Publication date: June 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 50Author(s): G. Spoletini, M. Kennedy, L. Flint, T. Graham, C. Etherington, N. Shaw, P. Whitaker, M. Denton, I. Clifton, D. PeckhamAbstractBackgroundThe increased prevalence of multi-drug resistant strains of P.aeruginosa and allergic reactions among adult patients with cystic fibrosis (CF) limits the number of antibiotics available to treat pulmonary exacerbations. Fosfomycin, a unique broad spectrum bactericidal antibiotic, might offer an alternative therapeutic option in such cases.AimTo describe the clinical efficacy, safety and tolera...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Characterisation of 40 mg/ml and 100 mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation
ConclusionAerosolized tobramycin 100 mg/ml solution delivered higher lung dose compared to tobramycin 40 mg/ml solution. Tracheal tube type or size did not influence the aerosol characteristics and delivery parameters. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults
In conclusion, BGF MDI 320/14.4/10 μg had a similar budesonide PK profile to BUD/FORM MDI 320/9 μg. No PK drug–drug interactions were observed when budesonide was added to glycopyrronium and formoterol fumarate dihydrate. These data support the use of budesonide 320 μg and 160 μg in future clinical trials of BGF MDI in COPD. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Mishandling of pMDI and DPI inhalers in asthma and COPD – Repetitive and non-repetitive errors
ConclusionsImproper inhalation technique is very common and the majority of errors made in inhalation technique are repetitive. This emphasizes the role of an ongoing verification and training of a proper inhalation technique in all patients that are regularly treated with inhalers. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD
ConclusionsThis is the first study to demonstrate that inhaled medication can be measured in hair samples from subjects with asthma and/or COPD. The results show that hair drug concentration data could potentially provide a record of historical adherence to inhaled therapeutics. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Is aging a "comorbidity" of asthma?
This article will discuss the multitude of factors that justify considering aging as a comorbidity of asthma. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Oropharyngeal administration of silica in Swiss mice: A robust and reproducible model of occupational pulmonary fibrosis
Publication date: August 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 51Author(s): Sachin Karkale, Amit Khurana, Mohd Aslam Saifi, Chandraiah Godugu, Venu TallaAbstractPulmonary fibrosis (PF) is a lethal end stage of interstitial lung disease with increasing prevalence. The disease burden of PF has seen a sharp surge in the past two decades owing to entry of heavy amount of particulate matter due to industrialization and urbanization. In this work, we developed an oropharyngeal aspiration model of silica (1.5 mg/mice) induced pulmonary fibrosis as a homogeneous, reproducible, simple and alternative strateg...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Impact of doxofylline in COPD: A pairwise meta-analysis
Publication date: August 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 51Author(s): Mario Cazzola, Luigino Calzetta, Paola Rogliani, Clive Page, Maria Gabriella MateraAbstractDoxofylline is an effective bronchodilator for relieving airway obstruction in patients with asthma or chronic obstructive pulmonary disease (COPD), and displays a better safety profile with respect to theophylline. Herein, we performed a pairwise meta-analysis of the currently available data to provide consistent and homogeneous findings on the impact of this xanthine in COPD patients. Results obtained from 820 patients were selected ...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

In vivo and in vitro investigation of anti-inflammatory and mucus-regulatory activities of a fixed combination of thyme and primula extracts
Publication date: August 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 51Author(s): Jan Seibel, Kirill Kryshen, Judit E. Pongrácz, Martin D. LehnerAbstractHypersecretion of viscous mucus is one of the hallmark symptoms of acute and chronic bronchitis and typically develops secondary to an inflammation of the airway epithelium. Bronchipret® TP film-coated tablets (BRO), a herbal medicinal product containing a fixed combination of thyme herb and primula root extracts, has been successfully used clinically for the treatment of acute bronchitis for more than two decades. However, the underlying pharm...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent
DiscussionBoth doses of BGF MDI were well tolerated in healthy subjects of Japanese descent and the systemic exposure to budesonide was dose proportional for BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg. The safety and pharmacokinetics for BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg in Japanese subjects were comparable to data from previous studies in Western populations, which suggests that the safety and efficacy profile of BGF MDI should be similar in Western and Japanese subjects. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Preparation, validation and user-testing of pictogram-based patient information leaflets for tuberculosis
ConclusionThe present study shows that there is significant improvement in the knowledge levels of the patients and volunteers after reading the validated leaflets. The P-PILs are found to be an effective educational tool for TB patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Effect of pirfenidone on gastric emptying in a rat model
ConclusionsAdministration of pirfenidone 30 min after a meal as a single-bolus dose or a divided dose over a 90-min period blunted pirfenidone's effect on inhibition of gastric emptying in rats compared with pirfenidone administration as a single-bolus dose coincident with a meal. Decreased gastric emptying, which is associated with pirfenidone administration, may be one of the contributing factors leading to GI tolerability issues associated with pirfenidone use in humans. Modification of the dosing regimen diminished this impact and may provide insight into possible mitigation strategies to minimize GI-related toxiciti...
Source: Pulmonary Pharmacology and Therapeutics - July 6, 2018 Category: Respiratory Medicine Source Type: research

Oropharyngeal administration of silica in Swiss mice: A robust and reproducible model of occupational pulmonary fibrosis
Publication date: Available online 28 June 2018 Source:Pulmonary Pharmacology & Therapeutics Author(s): Sachin Karkale, Amit Khurana, Mohd Aslam Saifi, Chandraiah Godugu, Venu Talla Pulmonary fibrosis (PF) is a lethal end stage of interstitial lung disease with increasing prevalence. The disease burden of PF has seen a sharp surge in the past two decades owing to entry of heavy amount of particulate matter due to industrialization and urbanization. In this work, we developed an oropharyngeal aspiration model of silica (1.5 mg/mice) induced pulmonary fibrosis as a homogeneous, reproducible, simple and alternative s...
Source: Pulmonary Pharmacology and Therapeutics - June 29, 2018 Category: Respiratory Medicine Source Type: research

Mishandling of pMDI and DPI inhalers in asthma and COPD – Repetitive and non-repetitive errors
Conclusions Improper inhalation technique is very common and the majority of errors made in inhalation technique are repetitive. This emphasizes the role of an ongoing verification and training of a proper inhalation technique in all patients that are regularly treated with inhalers. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - June 29, 2018 Category: Respiratory Medicine Source Type: research

Effect of pirfenidone on gastric emptying in a rat model
Conclusions Administration of pirfenidone 30 min after a meal as a single-bolus dose or a divided dose over a 90-min period blunted pirfenidone's effect on inhibition of gastric emptying in rats compared with pirfenidone administration as a single-bolus dose coincident with a meal. Decreased gastric emptying, which is associated with pirfenidone administration, may be one of the contributing factors leading to GI tolerability issues associated with pirfenidone use in humans. Modification of the dosing regimen diminished this impact and may provide insight into possible mitigation strategies to minimize GI-related toxicit...
Source: Pulmonary Pharmacology and Therapeutics - June 23, 2018 Category: Respiratory Medicine Source Type: research

Preparation, validation and user-testing of pictogram-based patient information leaflets for tuberculosis
Conclusion The present study shows that there is significant improvement in the knowledge levels of the patients and volunteers after reading the validated leaflets. The Pictogram-based Patient Information Leaflets are found to be an effective educational tool for TB patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - May 26, 2018 Category: Respiratory Medicine Source Type: research

Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent
Discussion Both doses of BGF MDI were well tolerated in healthy subjects of Japanese descent and the systemic exposure to budesonide was dose proportional for BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg. The safety and pharmacokinetics for BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg in Japanese subjects were comparable to data from previous studies in Western populations, which suggests that the safety and efficacy profile of BGF MDI should be similar in Western and Japanese subjects. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - May 12, 2018 Category: Respiratory Medicine Source Type: research

Impact of doxofylline in COPD: A pairwise meta-analysis
Publication date: August 2018 Source:Pulmonary Pharmacology & Therapeutics, Volume 51 Author(s): Mario Cazzola, Luigino Calzetta, Paola Rogliani, Clive Page, Maria Gabriella Matera Doxofylline is an effective bronchodilator for relieving airway obstruction in patients with asthma or chronic obstructive pulmonary disease (COPD), and displays a better safety profile with respect to theophylline. Herein, we performed a pairwise meta-analysis of the currently available data to provide consistent and homogeneous findings on the impact of this xanthine in COPD patients. Results obtained from 820 patients were selected f...
Source: Pulmonary Pharmacology and Therapeutics - May 10, 2018 Category: Respiratory Medicine Source Type: research

Impact of doxofylline in COPD: A pair-wise meta-analysis
Publication date: Available online 26 April 2018 Source:Pulmonary Pharmacology & Therapeutics Author(s): Mario Cazzola, Luigino Calzetta, Paola Rogliani, Clive Page, Maria Gabriella Matera Doxofylline is an effective bronchodilator for relieving airway obstruction in patients with asthma or chronic obstructive pulmonary disease (COPD), and displays a better safety profile with respect to theophylline. Herein, we performed a pair-wise meta-analysis of the currently available data to provide consistent and homogeneous findings on the impact of this xanthine in COPD patients. Results obtained from 820 patients were s...
Source: Pulmonary Pharmacology and Therapeutics - April 27, 2018 Category: Respiratory Medicine Source Type: research